Learning to Navigate the Neoadjuvant and Adjuvant Paradigms in Pancreatic Cancer

Newsfeed Image, Light Gray Text On Dark Gray Background
Neoadjuvant chemotherapy could become a standard approach for patients with resectable pancreatic cancer, with data suggesting that adjuvant regimens also have a place in the paradigm, said Tanios Bekaii-Saab, MD, a medical oncologist at Mayo Clinic.

Bekaii-Saab explained that patients with borderline resectable, resectable, and locally advanced nonmetastatic pancreatic cancer should receive neoadjuvant chemotherapy, as it enables a cleaner surgery and increases R0 resection rates. Read more . . .